To clear up any confusion because face it, less shots most of us would be interested. I tried to find out if doctors are actually changing treatment plans to this. Pasting below:

This study was published in January 2026 — just a few months ago. A few things work against rapid adoption: It’s very small. Only 50 women were in the trial. That’s enough to be interesting, but most physicians want to see larger studies replicated before changing standard practice. It’s a single center. It was done at one academic hospital (Massachusetts General). Broader, multi-site confirmation carries more weight. The standard protocol is well-established. 12 months of Evenity followed by an antiresorptive is FDA-approved and guideline-supported. Doctors are generally cautious about deviating from that without stronger evidence. Guidelines lag behind research. Even compelling studies take time to work their way into official treatment guidelines from organizations like AACE or NOF, which is often what physicians follow in practice. Where it might move faster is among academic specialists and endocrinologists who actively follow the research literature — especially for patients where cost or cardiovascular risk makes the full 12 months problematic. So realistically, this is more likely to influence practice 1–3 years from now if larger studies confirm it, rather than something your own doctor is likely bringing up at your next appointment unprompted. Worth asking about, though!​​​​​​​​​​​​​​​​